Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Telmisartan/Amlodipine FDC vs Mono-components
NCT02259803Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2007
- Primary completion
- Nov 2007
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of telmisartan and amlodipine in hypertension (HTN) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point up to 144 hours and Maximum measured concentration of the analyte in plasma up to 144 hours. Started Oct 2007; status: completed.
02
Drugs
telmisartanamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02259803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259803.